Exchange
NYSE
Every company in the roster listed on NYSE.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
21 of 21 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 PfizerPFE · NYSE | 76 assets: 41 approved, 11 Ph 3, 14 Ph 2, 10 Ph 1 | TavapadonPhase 3 · Parkinson's DiseaseReliable signal | 9 Oct 2026Sasanlimab · Phase 1 |
 Eli LillyLLY · NYSE | 68 assets: 28 approved, 13 Ph 3, 12 Ph 2, 14 Ph 1, 1 other | eloralintidePhase 3 · ObesityReliable signal | Nov 2026tirzepatide · Phase 3 |
 GlaxoSmithKlineGSK · NYSE | 59 assets: 27 approved, 15 Ph 3, 12 Ph 2, 4 Ph 1, 1 other | fluticasone propionate/salmeterolPhase 3 · AsthmaReliable signal | 13 Oct 2026Dostarlimab · Phase 1/2 |
 AbbVieABBV · NYSE | 57 assets: 19 approved, 10 Ph 3, 13 Ph 2, 14 Ph 1, 1 other | TavapadonPhase 3 · Parkinson's DiseaseReliable signal | Nov 2026Budigalimab · Phase 2 |
 NovartisNVS · NYSE | 57 assets: 29 approved, 9 Ph 3, 10 Ph 2, 9 Ph 1 | indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal | 5 Oct 2026Capmatinib · Phase 1 |
 Bristol-Myers SquibbBMY · NYSE | 49 assets: 20 approved, 10 Ph 3, 11 Ph 2, 8 Ph 1 | AzacitidinePhase 3 · Acute Myeloid LeukemiaPartial signal | 5 Oct 2026Xanomeline/trospium chloride · Phase 3 |
 Johnson & JohnsonJNJ · NYSE | 49 assets: 32 approved, 7 Ph 3, 7 Ph 2, 3 Ph 1 | SeltorexantPhase 3 · Major Depressive DisorderReliable signal | 30 Oct 2026bleximenib · Phase 1 |
 Merck & Co.MRK · NYSE | 34 assets: 12 approved, 14 Ph 3, 5 Ph 2, 3 Ph 1 | EnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 9 Oct 2026Alimatravir · Phase 1 |
 Novo NordiskNVO · NYSE | 28 assets: 9 approved, 8 Ph 3, 5 Ph 2, 6 Ph 1 | amycretinPhase 3 · ObesityReliable signal | Dec 2026UBT251 · Phase 1 |
 Takeda Pharmaceutical CompanyTAK · NYSE | 18 assets: 8 approved, 9 Ph 3, 1 Ph 2 | zasocitinibPhase 3 · Psoriatic ArthritisReliable signal | 17 Feb 2027zasocitinib · Phase 2 |
 Bausch HealthBHC · NYSE | 14 assets: 13 approved, 1 Ph 2 | amiselimodPhase 2 · Ulcerative ColitisReliable signal | Dec 2028brodalumab · Approved |
 Teva Pharmaceutical IndustriesTEVA · NYSE | 13 assets: 9 approved, 3 Ph 3, 1 Ph 1 | Olanzapine (TV-44749)Phase 3 · SchizophreniaReliable signal | 15 Jan 2027Anle138b · Phase 1 |
 OrganonOGN · NYSE | 12 assets: 7 approved, 4 Ph 3, 1 other | EzetimibePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Aug 2027Tapinarof · Phase 3 |
 Alto NeuroscienceANRO · NYSE | 6 assets: 6 Ph 2 | ALTO-100Phase 2 · Major Depressive DisorderPartial signal | Dec 2026ALTO-300 · Phase 2 |
 Amneal PharmaceuticalsAMRX · NYSE | 6 assets: 6 approved | Approved assets only | None on record |
 BiohavenBHVN · NYSE | 6 assets: 5 Ph 3, 1 Ph 2 | BHV-1400Phase 3 · Chronic Kidney Disease | Nov 2026Opakalim · Phase 1 |
 Dr. Reddy's LaboratoriesRDY · NYSE | 4 assets: 4 approved | Approved assets only | 31 Mar 2027Eribulin mesylate · Phase 1/2 |
 Emergent BioSolutionsEBS · NYSE | 3 assets: 3 approved | Approved assets only | None on record |
 Palatin TechnologiesPTN · NYSE | 3 assets: 1 Ph 3, 2 Ph 2 | PL9643Phase 3 · Dry Eye Disease | None on record |
 Nuvation BioNUVB · NYSE | 2 assets: 1 approved, 1 Ph 3 | safusidenibPhase 3 · Glioma | 2 Feb 2027Taletrectinib · Phase 1 |
 EvommuneEVMN · NYSE | 1 asset: 1 Ph 2 | EVO756Phase 2 · Migraine | Oct 2027EVO756 · Phase 2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).